CERO THERAPEUTICS HOLDINGS, INC.

Phoenix Biotech Acquisition Corp, trading under the ticker PBAX and sponsored by Phoenix Biotech Sponsor LLC, completed its initial public offering in 2021 with a stated focus on the biotechnology and life sciences sector. By mid-2022, the blank-check company was operating under the name Cero Therapeutics Holdings, Inc., reflecting its announced business combination with Cero Therapeutics, a clinical-stage biopharmaceutical company developing engineered T-cell receptor therapies targeting solid tumors and other cancers. The 10-Q filed with the SEC on August 11, 2022 documents the company's financial position during this de-SPAC transition period. Sign up at SpacDesk for full filings, sponsor data, and real-time status tracking on PBAX and hundreds of other SPACs.